OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 153 filers reported holding OCULAR THERAPEUTIX INC in Q1 2021. The put-call ratio across all filers is 0.82 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $70,635 | -1.9% | 13,689 | -20.8% | 0.00% | – |
| Q3 2022 | $72,000 | -51.4% | 17,291 | -53.1% | 0.00% | -100.0% |
| Q2 2022 | $148,000 | -25.6% | 36,891 | +85.3% | 0.00% | 0.0% |
| Q3 2021 | $199,000 | -59.6% | 19,913 | -42.6% | 0.00% | -50.0% |
| Q2 2021 | $492,000 | +49.5% | 34,681 | +73.2% | 0.00% | 0.0% |
| Q1 2021 | $329,000 | +53.7% | 20,026 | +94.1% | 0.00% | 0.0% |
| Q4 2020 | $214,000 | -75.9% | 10,315 | -91.2% | 0.00% | -83.3% |
| Q3 2020 | $889,000 | -28.5% | 116,846 | -21.7% | 0.01% | -40.0% |
| Q2 2020 | $1,243,000 | +886.5% | 149,257 | +487.1% | 0.02% | +566.7% |
| Q1 2020 | $126,000 | +186.4% | 25,424 | +77.2% | 0.00% | – |
| Q3 2019 | $44,000 | -55.6% | 14,348 | -35.5% | 0.00% | -100.0% |
| Q4 2017 | $99,000 | -32.2% | 22,243 | +41.6% | 0.00% | -33.3% |
| Q2 2017 | $146,000 | -71.4% | 15,703 | -74.3% | 0.00% | -85.7% |
| Q4 2016 | $510,000 | – | 60,985 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 6,122,089 | $32,263 | 100.00% |
| Opaleye Management Inc. | 6,105,900 | $32,178,093 | 9.64% |
| DELTEC ASSET MANAGEMENT LLC | 1,913,612 | $10,084,735 | 2.49% |
| Knoll Capital Management, LLC | 200,000 | $1,504,000 | 2.32% |
| Endurant Capital Management LP | 512,744 | $2,702,161 | 1.39% |
| Knoll Capital Management, LLC | 95,800 | $504,866 | 0.78% |
| Covestor Ltd | 60,008 | $316 | 0.28% |
| Ikarian Capital, LLC | 200,000 | $1,054,000 | 0.24% |
| EAM Investors, LLC | 224,211 | $1,181,592 | 0.23% |
| Nebula Research & Development LLC | 22,474 | $118,438 | 0.21% |